Drug research giant AbbVie announced a deal to buy cancer drug startup Stemcentrx in a $5.8 billion cash and stock deal this morning. The terms of the deal include $2 billion in cash and $3.8 billion in stock upfront, plus another $4 billion in milestone-based payouts to StemCentrx, and $3.8 in stock. The deal values the company at up to $10.2 billion, according to a memo from early… Read More
Source: TechCrunch